JP2022527398A5 - - Google Patents
Info
- Publication number
- JP2022527398A5 JP2022527398A5 JP2021559978A JP2021559978A JP2022527398A5 JP 2022527398 A5 JP2022527398 A5 JP 2022527398A5 JP 2021559978 A JP2021559978 A JP 2021559978A JP 2021559978 A JP2021559978 A JP 2021559978A JP 2022527398 A5 JP2022527398 A5 JP 2022527398A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- pharmaceutical composition
- days
- cycle
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833432P | 2019-04-12 | 2019-04-12 | |
| US62/833,432 | 2019-04-12 | ||
| PCT/US2020/027358 WO2020210418A1 (en) | 2019-04-12 | 2020-04-09 | Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527398A JP2022527398A (ja) | 2022-06-01 |
| JP2022527398A5 true JP2022527398A5 (cg-RX-API-DMAC7.html) | 2023-04-17 |
| JP7562557B2 JP7562557B2 (ja) | 2024-10-07 |
Family
ID=70465546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559978A Active JP7562557B2 (ja) | 2019-04-12 | 2020-04-09 | 2-(2,6-ジオキソピペリジン-3-イル)-4-((2-フルオロ-4-((3-モルホリノアゼチジン-1-イル)メチル)ベンジル)アミノ)イソインドリン-1,3-ジオンを使用する非ホジキンリンパ腫の処置方法 |
Country Status (27)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113573719A (zh) | 2018-11-08 | 2021-10-29 | 朱诺治疗学股份有限公司 | 治疗和t细胞调节的方法和组合 |
| AU2020369497C1 (en) * | 2019-10-21 | 2026-05-07 | Celgene Corporation | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione |
| IL292375A (en) | 2019-10-21 | 2022-06-01 | Celgene Corp | Solid forms include (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)metyl)benzyl)amino)isoindoline-1 3- Discussion and salts from them, and preparations that include the same and their use |
| AU2020372333B2 (en) * | 2019-10-21 | 2026-08-06 | Celgene Corporation | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| SMT202600194T1 (it) * | 2019-10-21 | 2026-05-12 | Celgene Corp | Combinazione di composti di 4-amminoisoindolin-1,3-dione sostituiti e di secondi agenti attivi per l'uso nel trattamento di una condizione maligna ematologica |
| HRP20231487T1 (hr) | 2019-10-21 | 2024-03-01 | Celgene Corporation | Postupci za liječenje hematoloških malignosti uporabom 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-diona |
| CN114885602A (zh) * | 2019-10-21 | 2022-08-09 | 新基公司 | 包含(s)-2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮的药物组合物及其使用方法 |
| IL307257A (en) * | 2021-03-29 | 2023-11-01 | Juno Therapeutics Inc | A combination of car cell therapy and an immunomodulatory compound for the treatment of lymphoma |
| US20240207281A1 (en) * | 2021-04-21 | 2024-06-27 | Celgene Corporation | Methods of treating b-cell lymphoma using combination therapy |
| CN117241802A (zh) * | 2021-04-21 | 2023-12-15 | 新基公司 | 使用2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮治疗非霍奇金淋巴瘤的方法 |
| AU2022300184A1 (en) | 2021-06-21 | 2023-11-16 | Celgene Corporation | Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione |
| WO2026099206A1 (en) | 2024-11-05 | 2026-05-15 | Celgene Corporation | Therapy for the treatment of non-hodgkin lymphoma |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2430669C (en) | 2000-11-30 | 2011-06-14 | The Children's Medical Center Corporation | Synthesis of 3-amino-thalidomide and its enantiomers |
| US8648096B2 (en) * | 2006-09-15 | 2014-02-11 | Celgene Corporation | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
| EP3351240B1 (en) | 2009-05-19 | 2019-04-10 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| SG183257A1 (en) * | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| WO2012177678A2 (en) * | 2011-06-22 | 2012-12-27 | Celgene Corporation | Isotopologues of pomalidomide |
| UA116544C2 (uk) * | 2012-08-09 | 2018-04-10 | Селджин Корпорейшн | Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| US20150297579A1 (en) | 2012-11-05 | 2015-10-22 | Celgene Corporation | Treatment of cancer with pomalidomide in a renally impaired subject |
| EP2981262A1 (en) * | 2013-04-02 | 2016-02-10 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
| NZ731789A (en) * | 2014-10-30 | 2019-04-26 | Kangpu Biopharmaceuticals Ltd | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
| JP7258009B2 (ja) * | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| CN118344338A (zh) * | 2018-04-23 | 2024-07-16 | 细胞基因公司 | 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途 |
-
2020
- 2020-04-08 AR ARP200101015A patent/AR119715A1/es unknown
- 2020-04-09 FI FIEP20722180.5T patent/FI3952880T3/fi active
- 2020-04-09 KR KR1020217036544A patent/KR102944213B1/ko active Active
- 2020-04-09 SM SM20260013T patent/SMT202600013T1/it unknown
- 2020-04-09 JP JP2021559978A patent/JP7562557B2/ja active Active
- 2020-04-09 PL PL20722180.5T patent/PL3952880T3/pl unknown
- 2020-04-09 EP EP20722180.5A patent/EP3952880B1/en active Active
- 2020-04-09 MX MX2021012507A patent/MX428518B/es unknown
- 2020-04-09 CA CA3132538A patent/CA3132538A1/en active Pending
- 2020-04-09 US US16/844,407 patent/US11390617B2/en active Active
- 2020-04-09 RS RS20251313A patent/RS67593B1/sr unknown
- 2020-04-09 AU AU2020270917A patent/AU2020270917B2/en active Active
- 2020-04-09 DK DK20722180.5T patent/DK3952880T3/da active
- 2020-04-09 LT LTEPPCT/US2020/027358T patent/LT3952880T/lt unknown
- 2020-04-09 SG SG11202111232RA patent/SG11202111232RA/en unknown
- 2020-04-09 BR BR112021020372A patent/BR112021020372A2/pt not_active Application Discontinuation
- 2020-04-09 SI SI202030706T patent/SI3952880T1/sl unknown
- 2020-04-09 PT PT207221805T patent/PT3952880T/pt unknown
- 2020-04-09 CN CN202080043197.0A patent/CN114144182B/zh active Active
- 2020-04-09 WO PCT/US2020/027358 patent/WO2020210418A1/en not_active Ceased
- 2020-04-09 MA MA055608A patent/MA55608A/fr unknown
- 2020-04-09 TW TW109112033A patent/TWI853014B/zh active
- 2020-04-09 HR HRP20251668TT patent/HRP20251668T1/hr unknown
- 2020-04-09 ES ES20722180T patent/ES3061998T3/es active Active
-
2021
- 2021-10-08 CL CL2021002651A patent/CL2021002651A1/es unknown
- 2021-10-10 IL IL287145A patent/IL287145A/en unknown
- 2021-10-11 ZA ZA2021/07668A patent/ZA202107668B/en unknown
-
2022
- 2022-06-24 US US17/848,976 patent/US12103923B2/en active Active
-
2024
- 2024-08-09 US US18/799,483 patent/US20240400548A1/en active Pending